PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsChlorpromazine
Chlorpromazine
Chlorpromazine, Thorazine (chlorpromazine) is a small molecule pharmaceutical. Chlorpromazine was first approved as Thorazine on 1982-01-01. It is used to treat acute intermittent porphyria, anxiety disorders, attention deficit and disruptive behavior disorders, child behavior disorders, and hiccup amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. In addition, it is known to target alpha-2B adrenergic receptor, D(3) dopamine receptor, short transient receptor potential channel 5, D(4) dopamine receptor, D(1A) dopamine receptor, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, alpha-2C adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 7, alpha-2A adrenergic receptor, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorpromazine
Tradename
Company
Number
Date
Products
THORAZINEGSKN-009149 DISCN1982-01-01
2 products, RLD
Hide discontinued
Chlorpromazine hydrochloride
Tradename
Company
Number
Date
Products
THORAZINEGSKN-009149 DISCN1982-01-01
9 products, RLD
THORAZINEGSKN-011120 DISCN1982-01-01
5 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aunt bees five flavorsOTC monograph final2015-03-12
bluzen - winter pine, wintermint, peppermint - kitOTC monograph not final2020-09-11
bluzen hand sanitizer wintermintOTC monograph not final2020-09-10
chlorpromazineANDA2023-07-24
chlorpromazine hciANDA2020-02-22
chlorpromazine hydrochlorideANDA2024-02-14
giant eagle wintermint with fluorideOTC monograph final2019-10-22
giant eagle wintermint zero alcoholOTC monograph final2019-10-22
hey humans whitening wintermint chillOTC monograph final2021-03-01
level wintermint five whitening formula anticavityOTC monograph final2011-05-09
Show 8 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acute intermittent porphyria—D017118—
anxiety disordersEFO_0006788D001008F41.1
attention deficit and disruptive behavior disordersHP_0010865D019958F91.3
child behavior disorders—D002653—
hiccup—D006606R06.6
nauseaHP_0002018D009325R11.0
psychotic disorders—D011618F20.81
schizophreniaEFO_0000692D012559F20
tetanusEFO_0005593D013742A35
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AA: Phenothiazines with aliphatic side-chain, antipsychotics
— N05AA01: Chlorpromazine
HCPCS
Code
Description
J3230
Injection, chlorpromazine hcl, up to 50 mg
Q0161
Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Clinical
Clinical Trials
31 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20—11349
Psychotic disordersD011618—F20.81——1113
Bipolar disorderD001714EFO_0000289F30.9———112
AggressionD000374EFO_0003015————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DeliriumD003693—R41.0—22——2
Covid-19D000086382—U07.1—12——2
Neonatal abstinence syndromeD009357EFO_0005799P96.1——1——1
NeoplasmsD009369—C80—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—11———2
Colonic neoplasmsD003110—C1811———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839HP_0002013R11.11————1
Psychomotor agitationD011595——1————1
Acute intermittent porphyriaD017118——1————1
Oral manifestationsD009912——1————1
TetanusD013742EFO_0005593A351————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9————11
RecurrenceD012008——————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
Gastroesophageal refluxD005764EFO_0003948K21————11
PainD010146EFO_0003843R52————11
GlaucomaD005901EFO_0000516H40————11
BehaviorD001519GO_0007610STY/T053————11
Social skillsD066107——————11
Spinal cord injuriesD013119EFO_1001919—————11
Muscle spasticityD009128HP_0001257—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameChlorpromazine
INNchlorpromazine
Description
Chlorpromazine is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. It has a role as a phenothiazine antipsychotic drug, an antiemetic, a dopaminergic antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and an anticoronaviral agent. It is a member of phenothiazines, an organochlorine compound and a tertiary amine.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
Identifiers
PDB—
CAS-ID50-53-3
RxCUI—
ChEMBL IDCHEMBL71
ChEBI ID3647
PubChem CID2726
DrugBankDB00477
UNII IDU42B7VYA4P (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Chlorpromazine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 32,215 documents
View more details
Safety
Black-box Warning
Black-box warning for: Chlorpromazine, Chlorpromazine hci, Chlorpromazine hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,249 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use